Frontera Therapeutics’ Hong Kong IPO Application Lapses, Focused on Recombinant AAV Gene Therapy
NewTimeSpace News: Per information published on the official website of the Hong Kong Stock Exchange, the Main Board listing application filed by Frontera Therapeutics on 23 December 2025 has recently lapsed after the six-month validity period expired. UBS Group and Haitong International served as joint sponsors upon the initial filing.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- NewTimeSpace | "The First AAV Gene Therapy Stock", Frontera Therapeutics Files for Hong Kong IPO
- ALEBUND-B (09637.HK): IPO Subscription Period Closes, Margin Subscription Totals HK$40.611 Billion, Listing Scheduled for 29 June
- BAIGE ONLINE(02672.HK): IPO Subscription Period Concludes, Margin Oversubscription Hits Over 51 Times, Listing Scheduled for 29 June
- ISOTeam Ltd Completes Issuance of Phase 005 Commercial Paper on SDAX Digital Securities Platform, Raising Approximately SGD 5.06 Million
